Quit Kit: Every Way Out of Nicotine, Ranked by Evidence, With Exact Instructions

The most effective quit plan is not the most heroic one. For adults quitting cigarettes, strong evidence supports varenicline, combination nicotine replacement, and several other paths. Correct use, behavioral support, and follow-up matter as much as choosing a product.

Counseling plus medication can more than double the chance of quitting compared with trying without either, according to current CDC guidance.1 The exact benefit changes with the medicine, support, population, and outcome. A difficult unaided attempt is not proof that you cannot quit. It is evidence that the next attempt deserves more help.

What matters most

• For adults quitting combustible cigarettes, varenicline and combination nicotine replacement are among the strongest U.S.-approved options. Their comparative estimates can overlap.
• Nicotine e-cigarettes improve six-month quitting versus nicotine replacement in current trials, but they are not FDA-approved cessation medicines and long-term risk remains uncertain.
• Technique changes outcomes. Gum that is chewed continuously, a patch removed too early, or too little short-acting NRT can look like treatment failure.
• Vaping cessation, adolescence, pregnancy, and serious mental illness need separate judgment. Adult cigarette evidence does not transfer automatically.
• One cigarette is a lapse, not an order to abandon treatment. Reassess the trigger, technique, dose, adherence, and support.

Zoom

What this ranking means

The primary comparison is evidence for adults quitting combustible cigarettes, using biochemically verified or clearly defined abstinence at six months or longer where available. Safety, FDA status, access, adherence burden, psychiatric evidence, and certainty appear separately. Close or indirect estimates do not justify a precise league table.2

Three categories must stay distinct:

1. FDA-approved adult cigarette-cessation medicines: varenicline, nicotine replacement products, and bupropion sustained release.
2. Interventions with cessation evidence but no FDA drug approval for cessation, including nicotine e-cigarettes.
3. Investigational or unavailable U.S. options, including cytisinicline as of the September 3, 2026 status check.

Evidence for adults quitting combustible cigarettes

The August 26, 2026 Cochrane living review included 90 completed studies, 29,044 participants, and 49 randomized trials. In seven studies with 2,544 participants, nicotine e-cigarettes produced more quitting than NRT, with the estimate above. Serious adverse events were uncommon, but comparisons were often imprecise, and longer, larger safety studies are needed. The evidence came from regulated nicotine products used in studies, not illicit THC vapes or every commercial disposable.3

The absolute estimate matters. Four additional quitters per 100 does not mean 59% will quit, and a risk ratio of 1.59 is not a 59-percentage-point increase. Absolute benefit depends on the quit rate in the comparison group. Continued e-cigarette use after smoking cessation was also common in trials, so ending cigarettes and ending all nicotine are separate outcomes.

No single network ranking can choose for a person. Varenicline may have the strongest single-drug evidence, but nausea or kidney function can change fit. Combination NRT may be easy to start without a prescription, but cost and correct technique matter. Bupropion may be attractive for some patients and unsafe for someone with seizures, an eating disorder, or abrupt alcohol withdrawal risk.

Access is part of effectiveness. A highly ranked medicine that cannot be obtained, tolerated, or taken consistently may be less useful than a solid option started today. Insurance, generic availability, work schedule, privacy, and the ability to attend follow-up should enter the decision explicitly.

The best comparison ends with a follow-up plan. Decide when success, partial control, side effects, or continued smoking will trigger a call. Treatment should be adjusted from observed response, not abandoned because the first week was imperfect.

Varenicline: strongest single medicine for many adults

Varenicline partially stimulates alpha4beta2 nicotinic receptors while blocking some of nicotine’s reinforcing effect. It reduces withdrawal and often makes a cigarette less rewarding.

The common U.S. schedule is 0.5 mg once daily on days 1 through 3, 0.5 mg twice daily on days 4 through 7, then 1 mg twice daily from day 8, usually for 12 weeks.4 A standard plan begins one week before the quit date. The current label also permits a flexible quit date after starting, generally during days 8 through 35, and a gradual approach for selected patients. This is prescription literacy, not permission to start or alter it without a prescriber.

Take it after food with a full glass of water to reduce nausea. Vivid dreams or insomnia may improve with clinician-guided timing or dose adjustment. Severe kidney impairment requires adjustment. If a dose is missed, do not double the next one. Contact the prescriber for severe rash, swelling, seizure, major mood or behavior change, suicidal thinking, or symptoms concerning for heart or neurologic trouble.

In EAGLES, varenicline and bupropion did not cause a significant excess in the trial’s prespecified moderate-to-severe neuropsychiatric composite compared with nicotine patch or placebo among enrolled adults, including a clinically stable psychiatric cohort. Varenicline was most effective in that trial.5 This does not mean zero risk or prove safety in every unstable illness.

A flexible quit approach can help someone who is not ready to name one immediate quit day. The point is still a planned reduction toward stopping, not indefinite dual use. A prescriber can explain the label’s window, decide whether a lower dose is appropriate for side effects, and arrange another course or longer treatment when evidence and history support it.

If nausea occurs, taking varenicline after food with water often helps. If dreams or insomnia become disruptive, report them rather than stopping silently. Severe agitation, suicidal thinking, mania, seizure, or allergic symptoms require urgent assessment. Ordinary transient nausea and a psychiatric emergency should not be collapsed into one warning.

Combination nicotine replacement: steady coverage plus rescue

A patch gives background nicotine. Gum or a lozenge treats breakthrough urges. Combination NRT is more effective than one form alone and is roughly comparable with other top options in network estimates.2

Patch

Follow the package because brands differ. Common U.S. labels begin on the quit date. People smoking more than 10 cigarettes per day commonly consider a 21 mg patch; lower use may start lower. Apply one patch to clean, dry, hairless skin in the morning and rotate sites. Many schedules step down across 8 to 12 weeks. If vivid dreams or insomnia occur, a 24-hour patch can often be removed at bedtime, recognizing that morning withdrawal may increase.6

Fold a used patch sticky sides together and keep it away from children and pets. Do not wear two patches unless a clinician directs it. Pre-quit patch loading has been studied but can be off-label and is not the default package instruction.

Gum

For cigarette smokers, common labeling selects 4 mg if the first cigarette is within 30 minutes of waking and 2 mg otherwise. When used alone, use one piece every one to two hours for the first six weeks, with at least nine pieces daily early on, then taper. Do not exceed 24 pieces per day.7

Chew slowly until tingling or a peppery taste appears, then park it between cheek and gum and hold it there about a minute while the nicotine absorbs. Repeat this chew-and-park cycle until the tingling stops, usually about 30 minutes. Continuous chewing causes hiccups, nausea, or jaw pain and reduces absorption. Avoid food and drinks, especially acidic beverages, for 15 minutes before and during use.

Lozenge

The same 30-minute waking rule commonly selects 4 mg or 2 mg. When used alone, take one every one to two hours for six weeks, with at least nine daily early on, then taper. Do not exceed five in six hours or 20 per day.8

Let it dissolve over 20 to 30 minutes, moving it occasionally. Do not chew or swallow it. Avoid food or drink for 15 minutes before and during use. Heartburn, nausea, and hiccups often signal technique or frequency problems.

Nicotine inhaler and nasal spray are prescription products in the United States. They deliver short-acting nicotine and can help people who need behavioral substitution or rapid control, but mouth, throat, or nasal irritation can limit use.

Combination NRT often fails through underuse rather than excess. Someone applies a patch but waits until craving is overwhelming before using gum. Another chews gum rapidly and becomes nauseated. A third removes the patch for work and spends the shift in withdrawal. A pharmacist can troubleshoot strength, timing, skin reactions, dental issues, and whether a lozenge is easier than gum.

Nicotine medicine is far less harmful than cigarette smoke for adults who smoke. Caution labels about recent heart attack, serious arrhythmia, unstable angina, pregnancy, breastfeeding, or age under 18 should prompt clinician or pharmacist advice, not a return to smoking. Severe palpitations, chest pain, fainting, or signs of overdose need urgent care.

Safe storage is part of treatment. Used patches retain nicotine. Gum and lozenges can look like candy. Fold used patches together, return products to secure packaging, and keep every form away from children and pets. Call Poison Control after a suspected ingestion rather than waiting for symptoms.

Bupropion sustained release

Bupropion affects norepinephrine and dopamine signaling and reduces withdrawal for some adults. A common label schedule begins one to two weeks before quitting, with 150 mg once daily for three days, then 150 mg twice daily at least eight hours apart, with labeled treatment of 7 to 12 weeks and 12 weeks commonly used.9 Swallow sustained-release tablets whole. Taking the second dose earlier in the day may reduce insomnia. Do not double a missed dose.

It is contraindicated with a seizure disorder, current or prior bulimia or anorexia nervosa, MAOI use concurrently or within 14 days of stopping an MAOI, another bupropion product, known hypersensitivity to bupropion, and abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs. A clinician should review bipolar history, blood pressure, other medicines, and seizure-threshold risks.

Bupropion’s antidepressant identity can create two errors. It should not be chosen automatically for every person with depression, and it should not be dismissed as “just a psychiatric drug.” For smoking cessation it has its own evidence and label. A prescriber still needs to distinguish unipolar depression from bipolar risk, review interacting medicines, and monitor mood.

Insomnia can often be reduced by keeping doses at least eight hours apart and avoiding a dose close to bedtime, within the prescribed plan. Dry mouth is common. A seizure, severe allergic reaction, dangerous mood change, or manic symptoms needs urgent contact rather than a routine next visit.

Cytisine and cytisinicline: evidence is not U.S. approval

Cytisine is a plant-derived partial nicotinic-receptor agonist used in some countries. Cytisinicline is the U.S. development name for the same active molecule. Network evidence supports efficacy, but products, schedules, and regulation differ.2

On June 22, 2026, the sponsor reported that FDA issued a complete response letter for cytisinicline, citing observations at a third-party manufacturing facility and unfinished labeling. The sponsor said FDA did not identify an efficacy or safety deficiency, planned a fourth-quarter 2026 resubmission, and projected possible approval in the first half of 2027.10 No subsequent FDA approval was located by September 3, 2026. Do not buy an overseas product and improvise a regimen from this article.

This status could change. A complete response letter means FDA did not approve the application in its current form; it is not a permanent scientific rejection of the molecule. Sponsor plans and efficacy claims are not approval, either. A future U.S. product would need its own final label, manufacturing resolution, and instructions.

Where nicotine e-cigarettes fit, and where they do not

The Cochrane result deserves a direct conversation with adult smokers. Some people quit cigarettes with nicotine e-cigarettes when other paths have not worked or are not acceptable. The therapeutic target should be complete displacement of combustible cigarettes, because adding vaping while continuing to smoke may retain much of the smoking risk.

U.S. FDA marketing authorization for a tobacco product is not approval as a cessation drug. The United Kingdom has integrated e-cigarettes more actively into smoking-cessation policy; U.S. agencies emphasize approved medications and do not approve commercial vapes as quit medicines. Jurisdiction and product regulation matter.

A plan should address what happens after cigarettes stop. Some people continue vaping to prevent relapse, while others want to taper nicotine later. Evidence does not establish one universal timetable. The priorities are ending combustion, avoiding dual use, preventing youth or household exposure, and reassessing persistent dependence.

Commercial disposables may differ from products tested in trials. Nicotine concentration, device power, reliability, contaminants, and labeling vary. THC cartridges from informal sources belong to a different risk category and should not be treated as evidence-based cigarette cessation.

Behavioral support makes medication work in a life

Choose a quit date or a structured cut-down-to-quit plan. Map high-risk cues: waking, driving, alcohol, meals, conflict, breaks, social media, and device access. Remove cigarettes, chargers, ashtrays, and saved products. Tell one person what kind of help is useful.

A widely used quitline framing of urge-surfing is the four Ds: delay, deep breathe, drink water, and do something else. The National Cancer Institute’s Smokefree.gov offers similar craving strategies, including doing something else, keeping the mouth busy, slow deep breathing, walking, and using nicotine replacement.11 These are ways to ride an urge, not a substitute for adequate medication. Quitline counseling, individual or group therapy, text programs, and digital tools can add accountability. In the United States, call 1-800-QUIT-NOW. For Spanish, call 1-855-DEJELO-YA (1-855-335-3569).

Plan around alcohol, a common lapse trigger. Change the venue, choose an alcohol-free period, leave early, or bring support. A slip calls for curiosity: What cue was missed? Was short-acting NRT available? Was the patch used consistently? Was the medication tolerated? What will change before the next similar moment?

Follow-up is a treatment ingredient. A check in the first week can catch uncontrolled withdrawal, nausea, insomnia, technique errors, or a smoking-related medication interaction. Later contact can address weight, alcohol cues, persistent vaping, and whether treatment should continue, change, or end.

Behavioral support should be concrete. Instead of “manage stress,” identify the 3 p.m. meeting, the drive past the store, or the argument after dinner. Rehearse what the hands, mouth, route, and phone will do in that exact minute. Put gum or lozenges where urges occur rather than where the plan was written.

Contingency management uses reliable rewards for verified behavior and has evidence in several substance-use settings. A personal reward plan can borrow the principle, though formal programs use more structured verification. Reinforcement should add a reason to continue, not turn a lapse into punishment.

Special situations need separate pathways

Mental illness

Do not wait indefinitely for perfect psychiatric stability. Coordinate follow-up, monitor mood and sleep, and keep emergency contacts clear. The polycyclic aromatic hydrocarbons in tobacco smoke, not nicotine itself, induce CYP1A2.12 Stopping combustible cigarettes can therefore raise clozapine or olanzapine levels even when nicotine continues through NRT or vaping, so dose review may be needed. Contact the prescriber promptly and never self-adjust.

Pregnancy and breastfeeding

Behavioral counseling is first-line in U.S. obstetric guidance. Medication requires an individualized discussion of continued smoking risk, pregnancy evidence, and product timing. Vaping is not recommended during pregnancy. Do not transfer adult trial rankings without qualification.13

Teens

No OTC label or adult regimen should be improvised for a teen. A 2025 American Thoracic Society guideline for adolescents aged 10 to 18 strongly recommended a counseling-based intervention, conditionally suggested a technology-based intervention, and conditionally suggested a trial of clinician-directed varenicline or bupropion in selected adolescents. Every recommendation rested on very low certainty evidence, and the panel reached no recommendation for or against nicotine replacement therapy because it could not achieve consensus.14 Approval ages and indications differ. A pediatric clinician should assess dependence, mental health, family context, and off-label use.

Quitting vaping

No medication was FDA approved specifically for vaping cessation as of the search date. In a 2025 three-group randomized trial, 261 participants ages 16 to 25 who vaped daily or near-daily and did not regularly smoke were assigned to varenicline plus weekly counseling and a texting program, identical placebo plus the same counseling and texting, or enhanced usual care consisting of the texting referral alone. Biochemically verified continuous abstinence at weeks 9 to 12 was 51% with varenicline versus 14% with placebo; through week 24, it was 28% versus 7%.15 The adjusted odds ratios were 6.5 and 6.0, respectively. This selected, motivated cohort does not establish a universal plan or independent medication use.

For vaping, map continuous access, flavors, chargers, bathroom use, nighttime use, and social-media cues. Cigarette data can guide care but should not be assumed identical.

The 2025 trial included counseling and text support in both medication and placebo groups. Its result should not be retold as a pill-only effect. Participants were treatment-seeking, daily or near-daily vapers who did not regularly smoke, so the findings do not directly answer dual use, younger adolescents, pregnancy, or occasional vaping.

A vaping quit plan may need environmental friction that cigarettes already had: leave the device out of the bedroom, remove backups, change online purchasing, and identify friends or feeds tied to use. These are cue interventions, not guarantees. Medication decisions still belong with a clinician, particularly under age 18.

Weight, slips, and switching

Appetite can rise after quitting, and some people gain weight. The amount varies. Extreme dieting during the first weeks can add stress and hunger, so prioritize stopping smoke, regular meals, movement, sleep, and later adjustment unless a clinician advises otherwise.

One cigarette does not automatically require stopping NRT. Resume the plan, remove remaining cigarettes, and review what happened. Continued smoking with NRT can increase nausea, dizziness, or palpitations, so concerning symptoms deserve medical advice. Repeated lapse, poor withdrawal control, side effects, pregnancy, psychiatric change, kidney disease, seizures, or an eating-disorder history warrants clinician or pharmacist review.

Extending, combining, retreating, or switching can be reasonable, but it should reflect evidence and medical context. It is not a punishment for “failing.”

The first weeks are not a final verdict. Concentration and sleep can fluctuate while nicotine withdrawal, caffeine changes, and routines settle. Because smoking speeds caffeine clearance, the same coffee intake can feel stronger after quitting. Reducing late-day caffeine may help some people, and clozapine or olanzapine users need the separate prescriber warning above.

Weight concern deserves respect without turning cigarettes into a weight medicine. Regular meals, protein and fiber, movement, sleep, and planned snacks can reduce chaotic eating. A clinician can address diabetes, eating-disorder history, or large weight changes. The health gain from stopping smoking is not canceled by modest weight gain.

Help ladder

1. Today: Call a national quitline, remove one barrier, or choose a planning date.
   • English: 1-800-QUIT-NOW
   • Spanish: 1-855-DEJELO-YA (1-855-335-3569)
2. Add support: Enroll in counseling or a text program and tell a trusted person how to help.
3. Add a clinician or pharmacist: Review varenicline, combination NRT, bupropion, interactions, pregnancy, adolescence, kidney disease, seizures, eating disorders, bipolar symptoms, or repeated relapse.
4. Urgent help: Call 911 for seizure, severe allergic reaction, collapse, severe chest symptoms, or major breathing trouble. Call or text 988 for suicidal crisis, mania with danger, or psychosis. Call Poison Control at 1-800-222-1222 for nicotine ingestion or concerning exposure.

Frequently asked questions

Is varenicline safe if I have depression or anxiety?

EAGLES was reassuring in enrolled clinically stable adults, but not every condition or crisis was represented. Use a prescriber and monitor mood, behavior, sleep, and suicidal thinking.

Is a patch plus gum better than one product alone?

On average, combination NRT is more effective than one NRT form. The patch provides steady coverage and gum or lozenges address breakthrough urges.

Can I start medicine before my quit date?

Varenicline and bupropion commonly begin before the quit date under prescription instructions. Standard patch labeling usually begins on the quit date. Follow the specific label and clinician plan.

Can vaping help me quit cigarettes?

Current trials show nicotine e-cigarettes can outperform NRT for six-month cigarette cessation. They are not FDA-approved cessation medicines, long-term risk is uncertain, and benefit depends on fully displacing cigarettes rather than dual use.

What should I do after one cigarette?

Protect immediate safety, then resume the plan. Review the cue, medication technique, adherence, and support. One lapse does not erase progress or automatically mean NRT must stop.

Make the plan concrete

Choose one evidence-based medication pathway when appropriate, add behavioral support, and set a follow-up date. If the first plan is uncomfortable or incomplete, adjust it with a clinician or pharmacist. A difficult attempt is data, not destiny. For the brain loop behind the urge, see The Ten-Second Hijack.

This article provides medication literacy, not a prescription. Follow your own U.S. product label and clinician because brand, formulation, age, pregnancy, kidney function, psychiatric history, seizures, eating disorders, and other medicines can change the plan.

Related reading on NP FADY

• The Ten-Second Hijack: Nicotine, Your Mood, and the Cigarette That Only Calms the Craving It Created

References

1. Centers for Disease Control and Prevention. Clinical Interventions to Treat Tobacco Use and Dependence. https://www.cdc.gov/tobacco/hcp/patient-care-settings/clinical.html

2. Lindson N, Theodoulou A, Ordóñez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev. 2023;9:CD015226. https://pubmed.ncbi.nlm.nih.gov/37696529/

3. Lindson N, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. Updated 2026-08-26. https://www.cochrane.org/evidence/CD010216_can-electronic-cigarettes-help-people-stop-smoking-and-do-they-have-any-unwanted-effects-when-used

4. DailyMed. Varenicline tablets, U.S. prescribing information (Par Health USA, LLC; label updated February 10, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e5c0ef3-3179-4d7b-bc76-901473c73ce8

5. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-2520. doi:10.1016/S0140-6736(16)30272-0. https://pubmed.ncbi.nlm.nih.gov/27116918/

6. Centers for Disease Control and Prevention. How to Use Nicotine Patches. https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/quit-smoking-medications/how-to-use-quit-smoking-medicines/how-to-use-a-nicotine-patch.html

7. Centers for Disease Control and Prevention. How to Use Nicotine Gum. https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/quit-smoking-medications/how-to-use-quit-smoking-medicines/how-to-use-nicotine-gum.html

8. Centers for Disease Control and Prevention. How to Use the Nicotine Lozenge. https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/quit-smoking-medications/how-to-use-quit-smoking-medicines/how-to-use-the-nicotine-lozenge.html

9. Centers for Disease Control and Prevention. How to Use Bupropion SR. https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/quit-smoking-medications/how-to-use-quit-smoking-medicines/how-to-use-bupropion-sr.html

10. Achieve Life Sciences. Complete Response Letter for cytisinicline NDA. 2026-06-22. https://ir.achievelifesciences.com/news-events/press-releases/detail/264/achieve-life-sciences-receives-complete-response-letter-from-fda-for-cytisinicline-nda

11. National Cancer Institute. Smokefree.gov, cope with cravings. https://smokefree.gov/challenges-when-quitting/cravings-triggers/how-manage-cravings

12. UK Medicines and Healthcare products Regulatory Agency. Smoking and smoking cessation: clinically significant interactions. https://www.gov.uk/drug-safety-update/smoking-and-smoking-cessation-clinically-significant-interactions-with-commonly-used-medicines

13. American College of Obstetricians and Gynecologists. Tobacco and Nicotine Cessation During Pregnancy. Committee Opinion No. 807. 2020, reaffirmed 2023. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/05/tobacco-and-nicotine-cessation-during-pregnancy

14. Bauer SE, Macrea M, Casey A, et al. Treatment of Nicotine Use in Adolescents Under 18 Years of Age: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2025;211(9):1584. https://pubmed.ncbi.nlm.nih.gov/40879357/

15. Evins AE, Cather C, Reeder HT, et al. Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial. JAMA. 2025. https://pubmed.ncbi.nlm.nih.gov/40266580/

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.